<DOC>
	<DOCNO>NCT02743611</DOCNO>
	<brief_summary>This study evaluate patient relapse refractory Acute Myeloid Leukemia ( AML ) advance hypomethylating agent-resistant myelodysplastic syndrome ( MDS ) autologous immune cell , call T cell , collect via apheresis . The T cell reinfused accord dose-finding schedule patient identify adequate lymphopenia provide homeostatic expansion adoptively transfer , engineer T cell therapeutic product . As safety measure , T cell program self-destruct switch destroy start react tissue ( Graft versus host disease ) .</brief_summary>
	<brief_title>Dose Finding Study Evaluating Safety Feasibility Patients With Relapsed Refractory Myeloid Neoplasms</brief_title>
	<detailed_description>This single arm , dose escalation/ de-escalation , single US center , unblinded , phase 1 study . Its main goal determine safety tolerability autologous genetically modify T cell ( BPX-701 ) subject relapse refractory AML advance hypomethylating agent-resistant MDS . Rimiducid ( AP1903 ) administrate treat uncontrolled BPX-701 toxicity , Cytokine Release Syndrome severe off-tumor/on-target toxicity .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Acute leukemia : Patients refractory relapse AML , acute promyelocytic leukemia ( APL ) . Patients monosomal complex karyotype may enroll time day 14 biopsy induction chemotherapy , residual disease identify . Patients must express HLAA2.01 myeloid blast must express PRAME . Absolute lymphocyte count ( ALC ) &gt; 300/mm^3 cluster differentiation ( CD ) 3+ &gt; 150 cells/ mm^3 . Patients relapse great 100 day stem cell transplant eligible unless active GVHD require systemic immunosuppressive therapy , define need &gt; 10 mg prednisone equivalent/day active use calcineurin inhibitor . Relapsed refractory AML MDS . AML patient must &gt; 5 % bone marrow blast study entry , without alternative causality ( e.g . bone marrow regeneration ) . a. Relapsed refractory AML accord Modified International Working Group Criteria AML . 1 . Relapsed : Bone marrow blast ≥5 percent ; reappearance blast blood 2 . Refractory : Failure achieve complete remission ( CR ) complete remission incomplete blood count recovery ( CRi ) induction chemotherapy MDS patient : 1 . High Grade MDS ( RAEB2 ) 1019 % blast , respond hypomethylation therapy 2 . RAEB1 RAEB2 MDS recurrence initial response . Age ≥ 18 year . Life expectancy least 2 month . Karnofsky performance status : &gt; 60 % . Informed consent obtain Patients come previous cancer therapy least 14 day prior cytotoxic agent , prior D0 , except hydroxyurea give need control hyperleukocytosis . Persistent clinically significant toxicity prior chemotherapy must great Grade 1 ( CTCAE 4.03 ) time enrollment . Salvage/lymphodepleting chemotherapeutic agent may give 3 day prior T cell reinfusion necessary control rapidly grow disease . Able meet local institutional criterion T cell apheresis collection . Renal function : 1 . All patient must calculate creatinine clearance &gt; 40 mL/min accord CockcroftGault Equation . 2 . Routine urinalysis must show clinically significant abnormality . Subject adequate organ function measure : . Adequate LFTs : Total bilirubin ≤ 3.0 x institutional upper normal limit ( ULN ) direct bilirubin &lt; 1.6 x ULN . ii . Alanine transaminase ( ALT ) /aspartate transaminase ( AST ) Alkaline Phosphatase ≤ 5 x ULN . iii . Cardiac : leave ventricular ejection fraction rest must ≥ 40 % . iv . Pulmonary : forced expiratory volume ( FEV ) 1 , force vital capacity ( FVC ) , carbon monoxide diffuse capacity ( DLCO ) ≥ 50 % predict ( correct hemoglobin ) . Acceptable coagulation status : International normalized Ratio ( INR ) / Prothrombin Time ( PT ) ≤ 1.5 time ULN . Partial thromboplastin time ( PTT ) &lt; 1.5 time ULN . For fertile men woman , agreement use effective contraceptive method study 3 month administration BPX701 . Patients follow eligible enrollment ( initiation BPX701 infusion ) study : Inadequate lymphocyte count collection . Bovine product allergy . History prior malignancy : ) associate current disease , ii ) previously treat curative intent therapy less 1 year ago except superficial skin cancer . Participation investigational drug study &lt; 28 day prior D0 ( BPX701 infusion ) . Uncontrolled leptomeningeal leukemic disease . Uncontrolled disseminate intravascular coagulation . Other serious illness medical condition , investigator 's opinion could hamper patient 's understanding study , compliance study treatment , and/or safety interpretation study result . These condition include ( restrict ) : 1 . Congestive heart failure angina pectoris ( New York Heart Association Class III IV ) except medically control . Uncontrolled hypertension malignant arrhythmia . 2 . Presence significant neurologic psychiatric disorder impair ability obtain consent . 3 . Uncontrolled bacterial , viral fungal infection . 4 . Known HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) positivity subject meeting selection criterion define Foundation Accreditation Cell Therapy ( FACT ) American Association Blood Banks ( AABB ) . Unwillingness inability comply procedure require protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BPX-701</keyword>
	<keyword>AP1903</keyword>
	<keyword>Rimiducid</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>Primary Refractory AML</keyword>
	<keyword>Relapsed AML</keyword>
	<keyword>Refractory Myeloid Neoplasms</keyword>
</DOC>